Foreign institutional investors (FIIs) have cut their stake in Jubilant Life Sciences by 220 basis points to 22.38 percent at the end of September 2014 quarter from 24.58 percent as on June 30, 2014. Meanwhile, Domestic institutional investors (DIIs) have reduced their shareholding in the company by 94 basis points to 2.06 percent at the end of September 2014 quarter from 3 percent as on June 30, 2014.
Moreover, non institutions were holding 21.54 percent stake at the end of September 2014 quarter, up 314 basis points from 18.4 percent as on June 30, 2014, while corporate bodies were holding 6.35 percent stake at the end of September 2014 quarter, up 54 basis points from 5.81 percent as on June 30, 2014. Further, promoters’ shareholding was unchanged at 54.02 percent at the end of September 2014.
Jubilant Life Sciences is engaged in manufacture and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.
